Annolyse
BriefingsCompaniesInsightsPrinciplesCompareChatWatchlist

Explore

  • Briefings
  • Companies
  • Insights
  • Compare

Resources

  • Search
  • Methodology

© 2026 Annolyse.

ChartsAnalysisChatData
  1. Charts
  2. Analysis
  3. Chat
  4. Data
  5. Sources
←Back to briefings
Savor (SVR) / HY23

Leverage hit 9.8x EBITDA as margins compressed on a 20.7% revenue lift

Revenue rose 20.7% but EBITDA fell 33.6%, cash turned net negative and gearing moved well above the historical range as venue capex doubled.

Consumer / Hospitality

SVR revenue trajectory

Revenue context before the current result.

↗
Loading chart...
FY26 was $55.2m, versus $56.6m in FY25.

SVR EBITDA margin

EBITDA margin across covered periods.

↗
Loading chart...
  • HY22 SVR: Outside range high ebitda margin. 12.3%; 3-period range 6.8% to 10.7%. EBITDA margin: 12.3%, above normal range; 3-period mean 8.1%, range 6.8%-10.7%.
  • FY22 SVR: Outside range low ebitda margin. 9.8%; 5-period range 10% to 14.5%. EBITDA margin: 9.8%, below normal range; 5-period mean 12.4%, range 10.0%-14.5%.
  • HY23 SVR: Outside range low ebitda margin. 6.8%; 3-period range 6.9% to 12.3%. EBITDA margin: 6.8%, below normal range; 3-period mean 10.0%, range 6.9%-12.3%.
  • FY26 SVR: Outside range high ebitda margin. 14.5%; 5-period range 9.8% to 14.2%. EBITDA margin: 14.5%, above normal range; 5-period mean 11.5%, range 9.8%-14.2%.
EBITDA margin: 14.5%, above normal range; 5-period mean 11.5%, range 9.8%-14.2%.

SVR operating cash flow

Operating cash flow across covered periods.

↗
Loading chart...
FY26 was $6.9m, versus $7.1m in FY25.

SVR working-capital movement

Operating working-capital absorption or release by reporting period.

↗
Loading chart...
  • HY21 SVR: Outside range low operating working-capital movement. $-8m; 3-period range $-1m to $0.2m. Operating working-capital movement: NZ$-8.0m, below normal range; 1/3 prior periods had builds averaging NZ$0.2m, and 1 had releases averaging NZ$-1.0m.
  • FY22 SVR: Outside range high operating working-capital movement. $0.2m; 5-period range $-3.4m to $0.1m. Operating working-capital movement: NZ$0.2m, above normal range; 1/5 prior periods had builds averaging NZ$0.1m, and 4 had releases averaging NZ$-1.8m.
  • FY23 SVR: Unprecedented low operating working-capital movement. $-3.4m; 5-period range $-3.1m to $0.2m. Operating working-capital movement: NZ$-3.4m, unprecedented low; 2/5 prior periods had builds averaging NZ$0.2m, and 3 had releases averaging NZ$-1.2m.
  • HY24 SVR: Outside range high operating working-capital movement. $0.2m; 3-period range $-8m to $0m. Operating working-capital movement: NZ$0.2m, above normal range; 0/3 prior periods had builds, and 2 had releases averaging NZ$-4.5m.
Operating working-capital movement: NZ$0.2m, above normal range; 0/3 prior periods had builds, and 2 had releases averaging NZ$-4.5m.
Release date
23 November 2022
Published
23 April 2026
Ask about this result
Sections⌄
  1. Charts
  2. Analysis
  3. Chat
  4. Data
  5. Sources

Key metrics

Numbers worth scanning first

HY23 vs HY22

Revenue

$20.7m

+20.7% ↑ vs $17.2m

EBITDA

$1.4m

-33.6% ↓ vs $2.1m

Net profit after tax

−$2.1m

Suppressed: metric quality flags mark this value as unsuitable for normal comparison.

Net cash inflow from operating activities

$1.6m

+45.4% ↑ vs $1.1m

Interim dividend per share

−16.0c

— vs —

Profit before tax

−$2.1m

Suppressed: metric quality flags mark this value as unsuitable for normal comparison.

Cash and cash equivalents

−$0.09m

Suppressed: metric quality flags mark this value as unsuitable for normal comparison.

Total assets

$54.9m

-8.0% ↓ vs $59.6m

What changed

Net debt / EBITDA reached 9.8x at HY23, well above Annolyse's historical baseline of 4.4x–7.5x (3-period mean 5.78x), even though gross borrowings actually fell to NZ$13.7m from NZ$14.2m

The ratio spike is driven from the denominator: EBITDA dropped to NZ$1.4m from NZ$2.1m (-33.6%) on 20.7% revenue growth to NZ$20.7m, so EBITDA margin compressed to 6.8%, below the historical range of 6.9%–12.3%.

Below EBITDA, PBT and NPAT both deteriorated to -NZ$2.1m from -NZ$0.8m (-183.1%), with no tax distortion (effective tax rate 0.0% in both periods). Operating cash flow rose to NZ$1.6m (+45.4%), but capex more than doubled to NZ$2.4m for the new Viaduct venue, leaving pre-lease free cash flow at -NZ$0.7m and the cash balance at -NZ$0.1m versus NZ$2.7m a year ago. Equity fell 24.1% to NZ$14.3m.

What matters

Leverage is well outside the historical envelope

  • 9.8x net debt / EBITDA versus a 5.78x mean and 7.5x prior peak puts the balance sheet in a more constrained position than at any point in the supplied baseline, and the move came from earnings deterioration rather than borrowing growth. This matters because incremental venue investment is being funded from a thinner equity base (NZ$14.3m, down NZ$4.5m) and a cash position that has already gone negative.
  • Operating leverage worked in reverse. Revenue grew 20.7% but EBITDA fell, so each dollar of incremental sales produced negative incremental EBITDA. With margin now at the lower edge of the historical range, the read is that cost inflation, pre-opening costs for Viaduct, or mix shift more than offset the revenue lift. The HY22 acquisition-affected comparable makes the 20.7% headline less clean than it looks.
  • Cash conversion looks strong but is flattered. OCF / EBITDA of 117.3% sits above the historical mean of 38.2%, but the ratio is elevated partly because EBITDA collapsed and partly because inventory days tightened to 5.9 (lower edge of the historical 5.6–28.0 range). Working capital cannot keep funding the gap if EBITDA stays at this level.

Expectations

No forward targets or quantitative guidance were supplied

Management commentary points to the Viaduct venue opening in November and "trading… exceeded expectations" in its first 10 days, which provides qualitative second-half support but is not quantifiable here. The supplied second-half shape table is distorted by FY22 impairments (HY22 was 91.8% of full-year revenue but EBITDA was -7.6%), so it offers no usable seasonality anchor.

The release does not support a view that 2H earnings will close the gap; it supports only the existence of new revenue capacity. The gap matters because leverage at 9.8x leaves little room if Viaduct ramps slower than the early commentary implies.

Quality of result

The revenue growth is real but the earnings read is weak

EBITDA fell despite a 20.7% top line, which means the underlying contribution from existing venues is going backwards before any drag from new-venue pre-opening costs. ROE moved to -14.9% from -4.0%, below the historical range of -4.0% to -2.2%, confirming that the deterioration is not a presentation artefact.

The cash story is less durable than the OCF line suggests. Operating cash of NZ$1.6m came alongside inventory days near a historical low, and capex of NZ$2.4m drove pre-lease FCF to -NZ$0.7m. Gross debt did fall NZ$0.5m, consistent with management's statement that NZ$2.5m of third-party debt was paid down in the period, but the funding for that pay-down ultimately came out of the cash balance, which moved from NZ$2.7m to slightly negative. This is balance-sheet-assisted rather than earnings-funded deleveraging.

Unresolved

Open questions

What is the EBITDA contribution from existing venues excluding Viaduct pre-opening costs, and is the underlying margin actually below 6.8%?
Why did EBITDA fall on 20.7% revenue growth — is it cost inflation, mix, or one-off opening costs that should not recur?
How is the company funding ongoing capex with cash already net negative, and what headroom remains on borrowing facilities at 9.8x net debt / EBITDA?
Will Viaduct's strong early trading translate into a 2H EBITDA step-up large enough to bring leverage back inside the historical 4.4x–7.5x range?
Is the inventory days tightening to 5.9 sustainable, or will normalisation reverse part of the operating cash flow lift?

This briefing cannot assess the standalone economics of the new Viaduct venue or remaining covenant and facility headroom because neither is disclosed in the supplied release excerpts.

Chat

Ask about SVR HY23

Ask follow-up questions about Savor's HY23 result.

Informational only. No buy, sell, hold, price-target, or personal financial advice.

Ask about SVR HY23

Informational only. No buy, sell, hold, price-target, or personal financial advice.

Sign in to chat

Sign in to ask questions about Savor's HY23 result.

What is the EBITDA contribution from existing venues excluding Viaduct pre-opening costs, and is the underlying margin actually below 6.8%?Why does "Leverage is well outside the historical envelope" matter?How strong was the cash and earnings quality in HY23?What should I watch next for SVR after HY23?

Checking account...

Data appendix

Show segment detail

Open to load segment breakdown.

Show analytical metrics

Open to load analytical metrics.

Show key metrics table

Open to load key metrics.

Sources

Current period

Savor Interim Financial Statements

HY23 / financial report↗

Savor Interim Results - Appendix 2

HY23 / results announcement↗

Savor Interim Results Announcement

HY23 / results release↗

Prior comparable period

Savor Interim Financial Statements

HY22 / financial report↗

Savor Interim Results Announcement

HY22 / results announcement↗

Savor Interim Results Announcement

HY22 / results release↗

Full-year context

Savor 2022 annual results release timing

FY22 / financial report↗

Release context

Savor 2022 Annual Meeting results

HY23 / commentary↗

Related insights

Cross-company views selected from the metrics in this briefing.

Leverage and balance-sheet risk

Net debt / EBITDA is 9.80x, +4.40x versus the prior comparable period.

→

Revenue growth context

Revenue growth was 20.7% for this reporting period.

→

Cash conversion quality

This result converted 117.3% of EBITDA to operating cash flow, +63.8pp versus the prior comparable period.

→

ROE and capital efficiency

ROE was -14.9%, -10.9pp versus the prior comparable period.

→
This briefing is based on available company filings and standard Annolyse calculations. It is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.

Get notified when SVR publishes next

Get the next Savor briefing and related NZX reporting-season updates by email.